丙型肝炎抗病毒治疗中的常见问题

焦健; 王江滨

丙型肝炎抗病毒治疗中的常见问题

焦健,
王江滨

详细信息

中图分类号: R512.6
计量
- 文章访问数: 1952
- HTML全文浏览量: 35
- PDF下载量: 956
- 被引次数: 0
出版历程
- 出版日期: 2007-04-20

摘要

HTML全文

参考文献(10)

[1]Fried MW, Shiffman ML, Reddy R, et al.Peg-interferon alfa-2aplus ribavirin for chronic hepatitis C virus infection[J].N Engl JMed, 2002, 347∶975-982

[2]Fried MW.Side effects of therapy of hepatitis C and their manage-ment[J].Hepatology, 2002, 36 (5) ∶S237-244.

[3]Zeuzem S, Diago M, Gane E, et al.Controlled study for the treat-ment of patients with chronic hepatitis C and persistently normal ALTlevels with Peginterferon alfa-2a (40Kd) (Pegasys) and Ribavirin (Copegus) [J].Hepatology, 2003, 38 (4) ∶Suppl 1.

[4]Bressler B, Guindi M, Tomlinson G, et al.High body mass index isan independent risk facotr for nonresponse to antiviral treatment inchronic hepatitis C[J].Hepatology, 2003, 38 (3) ∶639-644.

[5]Poynark T, Ratziu V, McHutchison J, et al.Effect of treatment withPeginterferon or interferon alfa-2b and Ribavirin on steatosis in pa-tients infected with hepatitis C[J].Hepatology, 2003, 38∶75-85.

[6]Foster GR, Fried MW, Hadziyannis SJ, et al.Treatment of chronichepatitis C with Peginterferon alfa-2a (40kD) (Pegasys) and Riba-virin (Copegus) :patients age has a marked influence on he individualestimated probability of achieving a sustained virologicalresponse[J].Hepatology, 2003, 38 (4) ∶Suppl 1.

[7]Davis GI, Wong JB, McHutchison JG, et al.Early virologic re-sponse to treatment with Peginterferon alfa-2b plus Ribavirin in pa-tients with chronic hepatitis C[J].Hepatology, 2003, 38 (3) ∶645-652.

[8]Torriani FJ, Rockstroh J, Rodriguez-Torres M, et al.Results of A-PRICOT:A randomized, partially blinded international trial evalua-ting Peginterferon 2a+Ribvirion vs.interferon+Ribvirion in thetreatment of HCV and HIV/HCV co-infection[R].Presented at the11thCongress on Retroviruses and Opportunistic Infections, SanFrancisco Feb 8-11, 2004, Abstract 112.

[9]Yoshida H, Shiratori Y, Moriyama M, et al.Interferon therapy re-duces the risk for hepatocellucar carcinoma:national surveillanceprograrn cirrhotic and non-cirrhotic patients with chronic hepatitis Cin Japan[J].Ann Intern Med, 1999, 131 (3) ∶174-181.

[10]Forns X, Garcia-Retarillo M, Serrano T, et al.Antivirial therapyof patients with decompensated cirrhosis to prevent recurrence of hep-atitis after liver transplantation[J].J Hepatol, 2003, 39∶389-396.

施引文献

资源附件(0)

访问统计